Key Highlights

  • Echo IQ Limited (ASX:EIQ) provided an update on its EchoSolv HF FDA application, with shares trading at $0.605, up 17.48%, during the Trading session on 17 September 2026.
  • The company believes there is a clear path forward to obtaining FDA clearance for EchoSolv HF, which it says could potentially be achieved over the coming quarters.
  • The FDA's Not Substantially Equivalent determination raised no concerns regarding the underlying technology or core functionality of EchoSolv HF, with matters cited limited to aspects of statistical analysis supporting clinical validation.
  • The company is assessing multiple pathways forward, including an administrative appeal, FDA Ombudsman review, or a new 510(k) submission, with no material impact reported to existing strategic partner agreements.

Echo IQ Limited (ASX:EIQ) shares traded at $0.605, up 17.48%, during the trading session on 17 September 2026. The AI and medical technology company recently provided an update on its recent engagement with the U.S. Food & Drug Administration regarding its initial EchoSolv HF 510(k) application, following the FDA's earlier Not Substantially Equivalent determination disclosed on 8 September 2026.

Nature of the FDA Determination

Following receipt of the FDA's Not Substantially Equivalent determination and ongoing review of documentation, Echo IQ said it believes there is a clear path forward to obtaining FDA clearance for EchoSolv HF, which it stated could be achieved over the coming quarters. The company has commenced work to address the issues cited by the FDA in issuing the determination and said it will continue to assess potential pathways forward alongside counsel and key regulatory advisors.

Following a review of the FDA's feedback, the company said it considers the matters cited to be limited to aspects of statistical analysis supporting clinical validation. The company's assessment has not identified concerns relating to the underlying technology or core functionality of the EchoSolv HF device, and it remains confident that clearance is achievable under the 510(k) route.

Potential Regulatory Pathways

Echo IQ identified multiple potential pathways to progress EchoSolv HF toward FDA clearance, including an administrative appeal of the Not Substantially Equivalent determination, seeking review through the FDA Ombudsman, or submitting a new 510(k) application. A potential administrative appeal would allow the company to challenge the FDA's scientific and regulatory conclusions and obtain further insight into its rationale. The company noted that timelines for this process are not strictly defined and, in certain circumstances, may be shorter than 90 days. If filed, an administrative appeal may result in the determination being overturned, the FDA reopening its review and potentially providing clearance, or the FDA requesting that the company resubmit a 510(k) application with clarified requirements.

The company is also considering whether to approach the FDA Ombudsman, which can assist in obtaining a procedural review of the determination and support the company's clearance application with the FDA review team. A 510(k) resubmission was identified as a further alternative that could be undertaken over the coming quarters. Echo IQ said it remains committed to working closely with the FDA to address all matters cited in its determination.

Impact on Strategic Partnerships

The company reiterated that there has been no material impact to its existing strategic partner agreements, including those with Advara HeartCare, Mayo Clinic, and Pro Medicus Limited. Echo IQ said it will keep investors and shareholders informed of its progress in obtaining clearance for EchoSolv HF.

Key Takeaways

Echo IQ's update on its EchoSolv HF FDA application outlines a company working through a Not Substantially Equivalent determination that it characterises as relating to statistical analysis supporting clinical validation rather than the underlying technology itself, with several regulatory pathways under active assessment, including administrative appeal, Ombudsman review, and resubmission. With clearance timelines not yet defined and existing strategic partnerships reported as unaffected, the coming quarters are likely to be a period of continued regulatory engagement as the company works toward its stated goal of achieving 510(k) clearance for its heart failure detection tool.